Saniona AB (SANION) AI Stock Analysis

• Market Cap: kr1.21B
• Dividend Yield: N/A
• Average Volume (3M): 760.69K
• Price to Earnings (P/E): 4.4
• Beta (1Y): -0.42
• Revenue Growth: 1533.99%
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): 0.17
• Shares Outstanding: 138,030,140
• 10 Day Avg. Volume: 649,722
• 30 Day Avg. Volume: 760,688
• PEG Ratio: 0.29
• Price to Book (P/B): 4.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr10.95
• Price Target Upside: 21.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: kr10.50 ▲(16.93%Upside)

Saniona AB exhibits strong financial performance and is attractively valued, which are the primary drivers of the overall score. However, bearish technical indicators temper the outlook as they suggest limited near-term price momentum.

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB is a Swedish biopharmaceutical company focused on discovering and developing innovative treatments for diseases related to the central nervous system, autoimmune disorders, metabolic diseases, and rare diseases. The company leverages its expertise in ion channel drug discovery and development to create novel therapeutics aimed at improving patient outcomes.

How the Company Makes Money

Saniona AB primarily generates revenue through collaborations and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, research funding, milestone payments, and potential royalties on sales of successfully developed drugs. In addition, Saniona may receive income from government grants and research funding, which support its ongoing research and development efforts. The company's proprietary drug development programs, if successfully commercialized, could also contribute to future revenue streams through direct sales or additional partnerships.

Saniona AB Financial Statement Overview

Summary

Saniona AB has shown a solid financial recovery and growth trajectory, transitioning from losses to profitability. Significant improvements in revenue, gross profit margin, net profit margin, and a reduction in leverage demonstrate a strong financial position.

Income Statement

Saniona AB has demonstrated impressive revenue growth, increasing from SEK 16.84M in 2023 to SEK 334.67M in 2024, showcasing a strong market traction in the biotechnology space. The gross profit margin improved significantly to 98.5% in 2024 from 69.9% in 2023, reflecting efficient cost management. Additionally, the net profit margin turned positive to 56.4% in 2024, indicating profitability after years of losses. However, the EBIT and EBITDA margins are high at 72.3% and 76.1%, respectively, showing robust operating performance.

Balance Sheet

The company's balance sheet shows strong financial stability, with a positive shift in stockholders' equity from negative SEK 21.94M in 2023 to positive SEK 231.82M in 2024. The debt-to-equity ratio decreased significantly to 0.05, underscoring a low leverage position which reduces financial risk. The equity ratio improved to 68.2%, highlighting a solid capital structure. This healthy financial position suggests reduced risk and potential for future growth.

Cash Flow

Saniona AB's cash flow statements reflect a remarkable turnaround. The free cash flow increased from negative SEK 85.66M in 2023 to positive SEK 249.07M in 2024, signaling strong cash generation capabilities. The operating cash flow to net income ratio is 1.32, indicating efficient cash management in relation to profits. Moreover, the free cash flow to net income ratio is 1.32, suggesting a healthy conversion of earnings into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	334.67M	16.84M	15.28M	10.48M	8.20M
Gross Profit	329.58M	11.78M	10.81M	5.85M	4.95M
EBITDA	251.90M	-68.28M	-196.00M	-398.86M	-64.64M
Net Income	188.71M	-95.81M	-245.36M	-410.90M	-73.43M
Balance Sheet
Total Assets	339.73M	64.14M	153.70M	440.25M	692.18M
Cash, Cash Equivalents and Short-Term Investments	303.26M	30.96M	111.71M	356.86M	573.87M
Total Debt	10.50M	71.41M	81.52M	99.77M	47.51M
Total Liabilities	107.92M	86.08M	100.99M	158.25M	88.72M
Stockholders Equity	231.82M	-21.94M	52.71M	282.00M	603.46M
Cash Flow
Free Cash Flow	249.07M	-85.66M	-282.52M	-346.52M	-179.71M
Operating Cash Flow	249.20M	-85.53M	-281.54M	-345.04M	-174.71M
Investing Cash Flow	-124.00K	-129.00K	6.84M	43.16M	99.51M
Financing Cash Flow	23.25M	-7.97M	-20.52M	50.60M	621.18M

Saniona AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.98
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Negative. The current price of 8.98 is below the 20-day moving average (MA) of 9.40, below the 50-day MA of 9.28, and above the 200-day MA of 7.15, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 43.99 is Neutral, neither overbought nor oversold. The STOCH value of 48.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SANION.

Saniona AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	69 Neutral	kr1.21B	4.39	152.78%	―	1533.99%	―
XBRANE	58 Neutral	kr427.48M	―	-47.73%	―	45.52%	93.35%
Sector *	52 Neutral	kr5.61B	10.15	-63.86%	2.10%	27.11%	26.73%
SYNACT	48 Neutral	kr1.09B	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.92B	―	-42.24%	―	―	-19.44%
IRLAB.A	38 Underperform	kr297.27M	―	-194.31%	―	1643.36%	50.36%
GUARD	32 Underperform	kr397.30M	―	-205.65%	―	―	24.25%

Saniona AB Corporate Events

Saniona Converts Remaining Convertibles with Fenja Capital

Saniona AB announced that Fenja Capital II A/S has requested the conversion of its remaining outstanding convertibles, totaling SEK 6 million, into shares. This conversion will result in the issuance of 1,941,747 new shares, increasing the total number of shares by approximately 1.41% and slightly diluting existing shares and votes. The move reflects Saniona’s ongoing financial maneuvers to manage its capital structure effectively.

Saniona Highlights Acadia Pharmaceuticals’ R&D Day Featuring ACP-711

Saniona announced that its partner, Acadia Pharmaceuticals, will host an R&D Day to discuss its neurological and rare disease pipeline, including ACP-711, a compound originally developed by Saniona. This event highlights the progress of ACP-711, which Saniona outlicensed to Acadia, and underscores the potential impact on Saniona’s operations through potential milestone payments and royalties.

Saniona Acquires Headquarters to Bolster Stability and Growth

Saniona has acquired its headquarters in Glostrup, Denmark, to ensure long-term operational stability and financial flexibility as it advances its clinical programs. This strategic move is expected to provide greater control over infrastructure and costs, with the potential for financial benefits due to the area’s transformation into a desirable residential district.

Saniona AB Annual Shareholders’ Meeting: Key Resolutions and Strategic Initiatives

Saniona AB held its annual shareholders’ meeting on May 28, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided against issuing dividends, and re-elected board members with new appointments in leadership roles. Additionally, the meeting authorized the board to issue new shares and adopted an employee option program, reflecting strategic moves to strengthen the company’s financial position and incentivize its workforce.

Saniona AB Reports Strong Q1 2025 with Key Developments

Saniona AB reported a strong start to 2025, with significant financial and operational milestones achieved in the first quarter. The company secured seed funding for its joint venture, advanced regulatory processes for tesofensine, and initiated manufacturing and toxicology studies for SAN2355. Additionally, Saniona extended its collaboration with Boehringer Ingelheim and completed a successful TO4 financing, strengthening its financial position and setting the stage for continued growth.

Saniona Appoints New CFO to Strengthen Financial Strategy

Saniona has appointed Johnny Stilou as Chief Financial Officer, bringing over 25 years of financial leadership experience to the company. His expertise in corporate finance and capital markets is expected to support Saniona’s financial strategy and investor relations as it advances its pipeline and seeks long-term financing solutions.